Results for this period
Full year1 October 2025–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In addition to active sales activities, capital investment in factories in the Industry segment had a positive effect, while the Medical segment increased through the adoption of new equipment. In the Academia and Life Science segments, orders for consumables and equipment fell below the same period of the previous fiscal year because they did not progress as planned.
No applicable items. There are no applicable notes regarding the going-concern assumption or material events.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025–30 September 2026 |
| Net Sales | ¥35,999 million (YoY +4.5%) |
| Operating profit | ¥798 million (YoY +54.0%) |
| Ordinary income | ¥908 million (YoY +52.6%) |
| Profit attributable to owners of the parent | ¥648 million (YoY +51.2%) |
| Net income per share | ¥719.41 |
| Operating Margin | 2.2% (1.5% in the previous fiscal year) |
| Equity ratio | End of the current fiscal period 45.6 / End of previous period 43 |
| Total assets | ¥19,667 million |
| Net assets | ¥9,071 million |
| Cash flows from operating activities | ¥2,739 million |
| Cash flows from investing activities | ¥-83 million |
| Cash flows from financing activities | ¥-74 million |
| Cash and cash equivalents at end of period | ¥3,492 million |
| Full-year earnings forecast | Net Sales ¥35,500 million (YoY -1.4%) / Operating profit ¥620 million (YoY -22.3%) / Ordinary income ¥706 million (YoY -22.3%) / Profit attributable to owners of the parent ¥472 million (YoY -27.2%) |
| Annual Dividend Forecast | ¥140 per share → ¥110 per share（-21.4%） |
| Payout ratio | 19.5% (fiscal year ended September 2026), 21.0% (forecast for the fiscal year ending September 2027) |
| Segment revenue | Industry ¥18,928,788 thousand (YoY +6.0%), Medical ¥14,824,218 thousand (YoY +4.8%), Academia & Life Sciences ¥2,246,564 thousand (YoY -7.9%) |
| Segment profit | Industry ¥1,814,860 thousand (YoY +9.2%), Medical ¥1,417,682 thousand (YoY +7.2%), Academia & Life Sciences ¥290,978 thousand (YoY -3.3%) |
| Depreciation and amortization | ¥164,681 thousand |
| Impairment loss | ¥15,371 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥12,545 thousand / Extraordinary loss Loss on disposal of non-current assets ¥619 thousand, Impairment loss ¥15,371 thousand |
| Disclosure regarding the going concern assumption | No applicable items. There are no applicable notes regarding the going-concern assumption or material events. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 960,000 |
| Treasury Shares at Period-End | 59,092 |
| Factors Behind Changes in Business Performance | In addition to active sales activities, capital investment in factories in the Industry segment had a positive effect, while the Medical segment increased through the adoption of new equipment. In the Academia and Life Science segments, orders for consumables and equipment fell below the same period of the previous fiscal year because they did not progress as planned. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The current fiscal year benefited from active sales activities, capital investment in factories in the Industry segment, and the adoption of new equipment in the Medical segment. The forecast for the next fiscal year incorporates the prolonged Russia-Ukraine conflict and higher prices for energy and other items resulting from issues in the Middle East.